IPO Details
Bidding Dates
03 Jul 24 - 05 Jul 24
Price Range ₹
960 - 1008
Total Equity
₹ 1953.01Cr
Lot Size
14
Exchange Status
NSE,BSE
IPO Doc
Subscription Rate
Non-Institutional Investor
7.21×
Qualified Institutional Buyers
195.83×
Employees
8.81×
Retail Investors
7.21×
Total subscription Rate
67.87×
IPO Timeline
Offer start
03 Jul 2024
Offer end
05 Jul 2024
Allotment
08 Jul 2024
Refund initiation
09 Jul 2024
Demat transfer
09 Jul 2024
Listing
10 Jul 2024
Offer start
03 Jul 2024
Offer end
05 Jul 2024
Allotment
08 Jul 2024
Refund initiation
09 Jul 2024
Demat transfer
09 Jul 2024
Listing
10 Jul 2024
About Company
Emcure Pharmaceutical is a prominent Indian pharmaceutical company that specializes in the development, manufacturing, and global marketing of a wide range of pharmaceutical products. It holds a leading position in India's pharmaceutical market in therapeutic areas such as gynecology, blood-related disorders, and HIV antivirals, based on its impressive sales performance during the Financial Year 2021.Distinguished by its focus on research and development, Emcure is recognized as an innovative company. Its product portfolio encompasses diverse forms of medication, including orals, injectables, and biologics. Additionally, Emcure has ventured into the field of mRNA technology and is actively involved in the development of a COVID-19 vaccine utilizing this platform. This expansion into cutting-edge mRNA technology has allowed Emcure to target a broader range of markets across more than 70 countries worldwide. Emcure's success can be attributed to its commitment to scientific advancement, robust manufacturing capabilities, and global marketing strategies.
Year Founded
16-04-1981
Promotor Details
Berjis Minoo Desai
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 83.21 | 78.11 |
| Share Capital | 150730468 | 147649282 |
Offer to Public
1,93,75,070.00 Cr
Project Details
- General corporate purposes - 1588.64cr
- General corporate purposes(1) - 0cr
- Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Com - 6000cr
Objectives
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our Company
- andGeneral corporate purposes.
Highlights
- Emcure excels in creating unique pharmaceutical products for specialized therapeutic areas with limited competition and high entry barriers.
- Emcure is in a favorable position to capitalize on its dominant market position within India.
- Emcure possesses an expansive and diverse range of products that are experiencing rapid growth in international markets.
- Emcure demonstrates robust expertise and a successful history in establishing and developing brands.
- Emcure has a wide-ranging and varied manufacturing capacity that spans across different products and areas.
Challenges
- Emcure's ability to maintain or raise its product prices may be impacted by pricing pressure from customers.
- Emcure faces potential challenges in obtaining, maintaining, or renewing the necessary licenses, permits, and approvals for its business operations.
- Emcure has not encountered any delays, interruptions, or reductions in the supply or transportation of its raw materials or finished products.
- Emcure has not experienced any slowdown or shutdown in its manufacturing or R&D operations.
- Emcure and other entities are subject to an investigation by the Competition Commission of India for alleged cartelization in marketing an oral anti-diabetes formulation, which may result in adverse orders or penalties.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2020 | 58,032.94 | 1,808.52 | 1,991.76 | 1,977.61 | 16.0177 |
| 2022 | 59,473.89 | 1,808.52 | 2,091.91 | 1,950.81 | 10.7868 |
| 2023 | 65,734.05 | 1,808.52 | 7,025.56 | 6,622.00 | 36.6156 |
| 2021 | 66,591.06 | 1,808.52 | 4,185.94 | 3,921.47 | 21.6833 |
| 2024 | 77,093.67 | 1,811.52 | 2,512.53 | 2,398.55 | 13.2625 |
